Stellar Biotechnologies

Stellar Biotechnologies is a biotechnology company. It markets Keyhole Limpet Hemocyanin (KLH), a pharmaceutical ingredient used in multiple therapeutic vaccine candidates for cancer, immune disorders, Alzheimer’s and inflammatory diseases.

TypeSubsidiary
Parent CompanyEdesa Biotech
HQPort Hueneme, US
Founded1999
Websitestellarbiotechnologies.com
Cybersecurity ratingAMore
Stellar Biotechnologies was founded in 1999 and is headquartered in Port Hueneme, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Stellar Biotechnologies

Frank R. Oakes

Frank R. Oakes

Chairman of the Board, President and Chief Executive Officer
Gary Koppenjan

Gary Koppenjan

Senior Director of Investor Relations and Communications
Gregory T. Baxter

Gregory T. Baxter

Executive Vice President of Corporate Development
Show more

Stellar Biotechnologies Office Locations

Stellar Biotechnologies has an office in Port Hueneme
Port Hueneme, US (HQ)
332 E Scott St
Show all (1)

Stellar Biotechnologies Financials and Metrics

Summary Metrics

Founding Date

1999

Total Funding

$24.3 m
In total, Stellar Biotechnologies had raised $24.3 m. Stellar Biotechnologies is a subsidiary of Edesa Biotech

Stellar Biotechnologies Revenue

Embed Graph
View revenue for all periods
Stellar Biotechnologies's revenue was reported to be $410.87 k in FY, 2019
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

372.1k758.7k1.3m228.3k211.8k410.9k

Cost of goods sold

662.9k580.8k818.6k250.0k133.3k101.3k

Gross profit

(290.8k)177.9k453.1k(21.8k)78.5k309.6k

Gross profit Margin, %

(78%)23%36%(10%)37%75%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

13.4m4.0m7.4m4.6m4.2m5.0m

Accounts Receivable

56.6k157.6k85.8k1.3k41.2k217.1k

Prepaid Expenses

128.6k181.1k358.7k123.7k86.9k397.0k

Inventories

557.3k249.4k68.1k224.3k
USDFY, 2014

Financial Leverage

1.9 x
Show all financial metrics

Stellar Biotechnologies Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Stellar Biotechnologies Online and Social Media Presence

Embed Graph

Stellar Biotechnologies News and Updates

Edesa Biotech and Stellar Biotechnologies Complete Business Combination

TORONTO, June 7, 2019 /PRNewswire/ -- Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, today reported that the previously announced business combination with Stellar Biotechnologies, Inc. (Nasdaq: SBOT) ("Stellar"), which was completed pursuant to a share exchange...

Stellar Biotechnologies Reports Second Quarter Financial Results

LOS ANGELES, May 8, 2019 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy and immuno-oncology development pipelines, today reported financial results for the three and six months ended March 31, 2019...

Stellar Biotechnologies Reports Fiscal Year 2018 Financial Results

LOS ANGELES, Nov. 30, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy and immuno-oncology development pipelines, today reported financial results for the fiscal year ended September 30, 2018 and...

Stellar Biotechnologies to Present at BlueTech Summit

LOS ANGELES, Oct. 31, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy and immuno-oncology development pipelines, announced today that Stellar President and CEO Frank R. Oakes will present at the...

Stellar Biotechnologies to Supply KLH to National Institutes of Health

LOS ANGELES, Sept. 5, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, autoimmune disease and cancers, among other diseases, announced today that it...

Stellar Biotechnologies Reports Third Quarter Financial Results

LOS ANGELES, Aug. 8, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancer, among other diseases, today reported financial results for the...

Stellar Biotechnologies Blogs

Stellar Biotechnologies Frequently Asked Questions

  • When was Stellar Biotechnologies founded?

    Stellar Biotechnologies was founded in 1999.

  • Who are Stellar Biotechnologies key executives?

    Stellar Biotechnologies's key executives are Frank R. Oakes, Gary Koppenjan and Gregory T. Baxter.

  • How many employees does Stellar Biotechnologies have?

    Stellar Biotechnologies has 15 employees.

  • What is Stellar Biotechnologies revenue?

    Latest Stellar Biotechnologies annual revenue is $410.9 k.

  • What is Stellar Biotechnologies revenue per employee?

    Latest Stellar Biotechnologies revenue per employee is $27.4 k.

  • Who are Stellar Biotechnologies competitors?

    Competitors of Stellar Biotechnologies include Alimera Sciences, Biogen and Ironwood Pharmaceuticals.

  • Where is Stellar Biotechnologies headquarters?

    Stellar Biotechnologies headquarters is located at 332 E Scott St, Port Hueneme.

  • Where are Stellar Biotechnologies offices?

    Stellar Biotechnologies has an office in Port Hueneme.

  • How many offices does Stellar Biotechnologies have?

    Stellar Biotechnologies has 1 office.